Publications en collaboration avec des chercheurs de Hospital General Universitario de Valencia (22)

2024

  1. Consensus Statement from the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis

    Actas Dermo-Sifiliograficas

  2. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain

    Dermatologic Therapy, Vol. 2024

  3. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

  4. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

2023

  1. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

    Journal of Investigational Allergology and Clinical Immunology

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  2. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760

  2. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  3. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741

2019

  1. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis

    Journal of the European Academy of Dermatology and Venereology, Vol. 33, Núm. 7, pp. 1214-1223

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2018

  1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800

  2. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

    Journal of Dermatological Treatment, Vol. 29, Núm. 4, pp. 334-346

2016

  1. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209

  2. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

    Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602

  3. Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations

    Actas Dermo-Sifiliograficas, Vol. 107, Núm. 3, pp. 194-206

  4. Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations

    Actas dermo-sifiliograficas, Vol. 107, Núm. 3, pp. 194-206

  5. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1